PUBLICATION

Global Business Reports

AUTHORS

Kevin Norchi, Laura Brangwin, Eduardo Arcos

British Columbia & Yukon Mining 2017 Pre-Release 2

April 26, 2017

Led by their political and economic stability, both British Columbia and Yukon have become increasingly attractive jurisdictions for investors and mining companies worldwide, as they boast substantial mineral wealth coupled with favorable business and regulatory environments. These attributes are of utmost importance at a time when global political uncertainty becomes a major risk factor across industries. Moreover, the long-lasting mining tradition in these Western Canadian jurisdictions has resulted in a myriad of leading companies serving the sector, particularly centered around Vancouver, a mining center of excellence. Across B.C., juniors are embarking on significant exploration programs this year, following renewed optimism from the investment community and appetite for new discoveries amid a perceived lack of early-stage exploration projects in the pipeline. In Yukon, the industry has experienced one of its most dynamic years in recent history, with majors from the likes of Goldcorp, Newmont, Agnico Eagle and Barrick entering the territory. As commodities and precious metals prices stabilize and economic conditions improve worldwide, investments flows are surging in B.C. and Yukon, and the industry is ready to embark on a new cycle.

RELATED INTERVIEWS MORE INTERVIEWS

Tembo Power is developing hydropower projects across Africa with a focus on DRC.
Chesser Resources is upbeat about its Diamba Sud gold resource in Eastern Senegal.
Robocon speaks with GBR about the outlook for its services in Peru.
"Our product innovation process involves gathering client feedback and submitting it to the factory, which determines which ideas to pursue based on economic considerations."

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

MORE PREVIOUSLY PUBLISHED

SUBSCRIBE TO OUR NEWSLETTER